Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
Control of hypertension (ie, reduction of blood pressure to less than or equal to 160/90 mmHg) in 40 mild to moderate hypertensives not responding adequately to hydrochlorothiazide was achieved by the addition of guanfacine (once daily) or methyldopa (twice daily) in a 16-week, double-blind, parallel-group trial. Control occurred after two weeks (at 1 mg/day) in 50% of the guanfacine-treated patients and in most patients within four to six weeks of treatment. The final mean doses were 2.5 mg/day of guanfacine or 763 mg/day of methyldopa. Sixteen patients maintained control of hypertension with continued guanfacine therapy for one year.
D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D016316:Guanfacine; D006146:Guanidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010648:Phenylacetates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D013997:Time Factors
D000959:Antihypertensive Agents; D006146:Guanidines; D010648:Phenylacetates; D006852:Hydrochlorothiazide; D016316:Guanfacine; D008750:Methyldopa